Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 5/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CFD | P00746 | 2/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | GYS1 | P13807 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7314411 | 1.00 | LTB4R (0.49) | LTB4RLTB4R2EGFRIGF1RFLT4 | |
| SCHEMBL7320930 | 0.90 | PDCD1 (0.46) | GYS1 | |
| SCHEMBL7309258 | 0.85 | CFD (0.42) | EGFRIGF1RFLT4KDRCFD | |
| SCHEMBL7309274 | 0.85 | CFD (0.42) | EGFRIGF1RFLT4KDRCFD | |
| SCHEMBL7310606 | 0.82 | GYS1 (0.39) | LTB4RLTB4R2EGFRIGF1RFLT4 | |
| SCHEMBL7314504 | 0.73 | LTB4R (0.53) | LTB4RLTB4R2EGFRIGF1RFLT4 | |
| SCHEMBL19234110 | 0.73 | CFD (0.80) | CFD | |
| SCHEMBL7310670 | 0.72 | LTB4R (0.53) | LTB4RLTB4R2EGFRIGF1RFLT4 | |
| SCHEMBL7318362 | 0.72 | EGFR (0.54) | LTB4RLTB4R2EGFRIGF1RFLT4 | |
| SCHEMBL7310577 | 0.72 | LTB4R (0.52) | LTB4RLTB4R2EGFRIGF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | LTB4R 1512/4885LTB4R2 1564/4885EGFR 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.